[Clinical analysis of nosocomial infection of extended spectrum beta-lactamase-producing bacteria].
OBJECTIVE
To investigate the clinical characteristics of nosocomial infection of extended spectrum beta-lactamase(ESBL)- producing bacteria.


METHODS
The data of 50 cases of ESBL(+) E. coli and K. pneumonia from January to November 1999 in Peking Union Medical Hospital were analysed; 45 cases of ESBL (-) infection were randomly selected as controls. t-test and chi-square tests were used for statistical analysis.


RESULTS
Long time hospitalization and use of the third generation cephalosporins were risk factors for ESBL(+) pathogen infection(P < 0.02); the prevalence of ESBL(+) bacteria infection in abdominal and pelvic cavity was higher than that of ESBL(-) bacteria(P < 0.02); the outcome of properly treated group(sensitive antibiotics were used within 72 hours) was much better than improperly treated group. All ESBL(+) bacteria were sensitive to imipenam, the resistance rate of ESBL(+) bacteria to cefmetazole, amikacin and piperacillin/tazobactam was low; the in vitro activity of ceftazidim to ESBL(+) bacteria was high but the in vivo activity is still under study.


CONCLUSIONS
The mortality of ESBL(+) bacteria infection was high; the outcome would be improved if sensitive antibiotics were chosen as soon as the diagnosis was made.
Cao
B
B
Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
Wang
H
H
Chen
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy / Q000401:mortality*; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases